Literature DB >> 33065795

Pulmonary function of patients with 2019 novel coronavirus induced-pneumonia: a retrospective cohort study.

Dongqing Lv1, Xi Chen1, Xiaodan Wang1, Linghong Mao1, Jiao Sun1, Guixian Wu1, Zhi Lin1, Ronghai Lin2, Jiansong Yu3, Xiaomai Wu4, Yongpo Jiang5.   

Abstract

BACKGROUND: The aim of this study was to investigate the pulmonary function of patients with 2019 novel coronavirus (COVID-19)-induced pneumonia.
METHODS: A retrospective analysis of 137 patients with COVID-19-induced pneumonia who were discharged from the Enze Hospital, Taizhou Enze Medical Center (Group) from January 31 2020 to March 11 2020 was conducted. Follow-up occurred 2 weeks after hospital discharge, during which patients underwent a pulmonary function test.
RESULTS: Of the 137 patients who underwent a pulmonary function test 2 weeks after discharge, 51.8% were male, and the mean age was 47 years. Only 19.7% of the patients were identified as having severe COVID-19-induced pneumonia. The pulmonary function tests showed that for a small number of patients the forced expiratory volume in one second/forced vital capacity ratio (FEV1/FVC)/% values were <70%, and the mean forced inspiratory volume (IVC) and FVC values were 2.4±0.7 and 3.2±0.8 L, respectively. In severe cases, 88.9% of patients had an IVC <80% of the predicted value, and 55.6% of patients had an FVC <80% of the predicted value. The proportion of patients with maximum expiratory flow rate at 25%, 50% and 75% of the vital capacity (MEF25, MEF50, and MEF75) values <70% were 55.6%, 40.7%, and 25.9%, respectively. In the non-severe group, 79.1% of patients had an IVC <80% of the predicted value, and 16.4% of patients had an FVC <80% of the predicted value. The mean MEF25, MEF50, and MEF75 <70% values were 57.3%, 30%, and 13.6%, respectively.
CONCLUSIONS: Our results demonstrated that the pulmonary function of patients with COVID-19-induced pneumonia predominantly manifested as restrictive ventilation disorder and small airway obstruction, which was increased in critically ill patients.

Entities:  

Keywords:  COVID-19-infected pneumonia; pulmonary fibrosis; pulmonary function; restrictive ventilation disorder

Mesh:

Year:  2020        PMID: 33065795     DOI: 10.21037/apm-20-1688

Source DB:  PubMed          Journal:  Ann Palliat Med        ISSN: 2224-5820


  7 in total

1.  Could routine race-adjustment of spirometers exacerbate racial disparities in COVID-19 recovery?

Authors:  Meredith A Anderson; Atul Malhotra; Amy L Non
Journal:  Lancet Respir Med       Date:  2020-12-10       Impact factor: 30.700

Review 2.  Post-COVID lung fibrosis: The tsunami that will follow the earthquake.

Authors:  Zarir F Udwadia; Parvaiz A Koul; Luca Richeldi
Journal:  Lung India       Date:  2021-03

3.  Chloroquine and COVID-19: role as a bitter taste receptor agonist?

Authors:  B Bouazza; I Ramdani; R Chahed
Journal:  New Microbes New Infect       Date:  2021-01-24

Review 4.  Pulmonary function and COVID-19.

Authors:  Max Thomas; Oliver J Price; James H Hull
Journal:  Curr Opin Physiol       Date:  2021-03-26

5.  A prolonged steroid therapy may be beneficial in some patients after the COVID-19 pneumonia.

Authors:  Sabina Kostorz-Nosal; Dariusz Jastrzębski; Michał Chyra; Piotr Kubicki; Michał Zieliński; Dariusz Ziora
Journal:  Eur Clin Respir J       Date:  2021-06-24

6.  Integrative genomic analyses identify susceptibility genes underlying COVID-19 hospitalization.

Authors:  Gita A Pathak; Kritika Singh; Tyne W Miller-Fleming; Frank R Wendt; Nava Ehsan; Kangcheng Hou; Ruth Johnson; Zeyun Lu; Shyamalika Gopalan; Loic Yengo; Pejman Mohammadi; Bogdan Pasaniuc; Renato Polimanti; Lea K Davis; Nicholas Mancuso
Journal:  Nat Commun       Date:  2021-07-27       Impact factor: 17.694

7.  Parenchymal lung abnormalities following hospitalisation for COVID-19 and viral pneumonitis: a systematic review and meta-analysis.

Authors:  Laura Fabbri; Samuel Moss; Fasihul A Khan; Wenjie Chi; Jun Xia; Karen Robinson; Alan Robert Smyth; Gisli Jenkins; Iain Stewart
Journal:  Thorax       Date:  2022-03-25       Impact factor: 9.139

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.